Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2024-09-12 , DOI: 10.1002/alz.14185
Roxane Dilcher _{1,

2} , Stephan Wall ₂ , Mattes Groß ₃ , Sabrina Katzdobler _{4,

5,

6} , Olivia Wagemann ₅ , Carla Palleis _{4,

5,

6} , Endy Weidinger ₅ , Urban Fietzek ₅ , Alexander Bernhardt _{5,

6} , Carolin Kurz ₇ , Christian Ferschmann ₂ , Maximilian Scheifele ₂ , Mirlind Zaganjori _{2,

7} , Johannes Gnörich ₂ , Katharina Bürger _{3,

6} , Daniel Janowitz ₃ , Boris-Stephan Rauchmann _{7,

8} , Sophia Stöcklein ₉ , Peter Bartenstein ₂ , Victor Villemagne _{10,

11} , John Seibyl ₁₂ , Osama Sabri ₁₃ , Henryk Barthel ₁₃ , Robert Perneczky _{4,

6,

7} , Florian Schöberl ₅ , Andreas Zwergal _{5,

14} , Günter U Höglinger _{4,

5,

6} , Johannes Levin _{4,

5,

6} , Nicolai Franzmeier _{3,

4,

15} , Matthias Brendel _{2,

4,

6}

Affiliation

Neuroscience, Monash University, Melbourne, Australia.
Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, München, Germany.
Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, München, Germany.
(SyNergy), Munich Cluster for Systems Neurology, München, Germany.
Department of Neurology, University Hospital of Munich, LMU Munich, München, Germany.
(DZNE), German Center for Neurodegenerative Diseases, München, Germany.
Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, München, Germany.
Institute for Neuroradiology, University Hospital of Munich, LMU Munich, München, Germany.
Department of Radiology, University Hospital of Munich, LMU Munich, München, Germany.
Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia.
Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
German Center for Vertigo and Balance Disorders (DSGZ), University Hospital of Munich, LMU Munich, München, Germany.
Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Mölndal and Gothenburg, Sweden.

Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.

中文翻译：

结合脑脊液和 PI-2620 tau-PET 用于阿尔茨海默病和 4R-tau 病的基于生物标志物的分层

生物标志物研究的最新进展改善了阿尔茨海默病（AD）的诊断和监测，但目前缺乏基于体内生物标志物的工作流程来评估 4R-tau 蛋白病（4RT）患者。我们建议使用一种新的基于生物标志物的算法来表征 AD 和 4RTs。

更新日期：2024-09-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文